- In April 2023, InVivo Therapeutics announced positive safety data from its clinical evaluation of the Neuro-Spinal Scaffold, a bioresorbable polymer device designed to support tissue healing following acute spinal cord injury. The interim analysis from the INSPIRE 2.0 study indicated promising neurological improvements in some patients, reinforcing the company’s commitment to advancing regenerative solutions for spinal trauma. This development represents a critical step toward the commercialization of biomaterial-based spinal cord therapies
- In March 2023, Asterias Biotherapeutics, in collaboration with leading academic centers, reported updated clinical outcomes from trials using its investigational stem cell therapy, AST-OPC1, targeting cervical spinal cord injuries. The treatment demonstrated sustained motor function improvement in patients, highlighting the potential of oligodendrocyte progenitor cell therapy to promote nerve repair. These findings strengthen the role of stem cell-based approaches in transforming acute SCI treatment landscapes
- In March 2023, BioArctic AB announced preclinical progress on its BrainRepair program, focused on restoring lost function after central nervous system injuries, including acute spinal cord trauma. The company’s research into antibody-based therapies seeks to inhibit nerve growth inhibitors post-injury, fostering neuronal regeneration. BioArctic’s ongoing innovation underscores a shift toward disease-modifying treatments in spinal cord injury care
- In February 2023, ReNetX Bio disclosed advancements in its NoGo Trap therapy, a novel biologic candidate aimed at restoring neural connectivity by blocking inhibitory molecules that prevent axonal growth. Supported by the National Institutes of Health (NIH), the therapy has shown potential in early-stage studies for acute SCI and represents a new direction in regenerative medicine that targets molecular barriers to recovery
- In January 2023, the Craig H. Neilsen Foundation announced expanded funding for acute SCI research, awarding grants to institutions exploring novel neuroprotective strategies and early intervention protocols. This initiative emphasizes the importance of cross-sector collaboration to accelerate therapeutic development and clinical readiness. By funding multi-disciplinary efforts, the Foundation is playing a key role in shaping the future of acute spinal cord injury treatment and rehabilitation
